Boehringer's Dulcolax in agency review; Roche rolls back hep C drug prices in India;

> Boehringer Ingelheim's Dulcolax brand kicked off a global creative review, with pitches taking place at the end of June. Report

> Roche ($RHHBY) rolled back the prices on its Exxura treatment for hepatitis C in India, cutting the price by 65% for government institution purchasers. Report

> Bayer and Johnson & Johnson ($JNJ) have presentations on their anticoagulant drug Xarelto scheduled at the International Society on Thrombosis and Haemostasis meeting. Report

> Merck Serono won two prestigious Red Dot Awards for the design of its fertility drug-delivery pens. Release

> Rovi signed up to market Orvatez, a cholesterol-fighting drug that combines Merck & Co.'s ($MRK) Zetia (ezetimibe) with the statin drug atorvastatin, in Spain. Report

And Finally... The biosimilar naming debate is heating up as the FDA plans new guidance by the end of the year. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?